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Am J Geriatr Psychiatry&&:&&,&& 201Objective: Studies have shown that antidepressants are no better than placebo
in treating depression in dementia. The authors examined antidepressant effi-
cacy in subgroups of depression in dementia with different depressive symptom
profiles. Methods: This study focuses on exploratory secondary analyses on the
randomized, parallel-group, double-blind, placebo-controlled Health Technol-
ogy Assessment Study of the Use of Antidepressants for Depression in Dementia
(HTA-SADD) trial. The setting included old-age psychiatry services in nine cen-
ters in England. The participants included 326 patients meeting National Insti-
tute of Neurological and Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association probable/possible Alzheimer disease
criteria, and Cornell Scale for Depression in Dementia (CSDD) scores of 8 or
more. Intervention was placebo (n = 111), sertraline (n = 107), or mirtazapine
(n = 108). Latent class analyses (LCA) on baseline CSDD items clustered partici-
pants into symptom-based subgroups. Mixed-model analysis evaluated CSDD
improvement at 13 and 39 weeks by randomization in each subgroup.
Results: LCA yielded 4 subgroups: severe (n = 34), psychological (n = 86), affec-
tive (n = 129), and somatic (n = 77). Mirtazapine, but not sertraline, outper-
formed placebo in the psychological subgroup at week 13 (adjusted estimate:
−2.77 [standard error (SE) 1.16; 95% confidence interval: −5.09 to −0.46]),
which remained, but lost statistical significance at week 39 (adjusted estimate:Key Words:
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2−2.97 [SE 1.59; 95% confidence interval: −6.15 to 0.20]). Neither sertraline nor
mirtazapine outperformed placebo in the other subgroups. Conclusion: Because
of the exploratory nature of the analyses and the small sample sizes for subgroup
analysis there is the need for caution in interpreting these data. Replication of the
potential effects of mirtazapine in the subgroup of those with depression in
dementia with “psychological” symptoms would be valuable. These data should
not change clinical practice, but future trials should consider stratifying types of
depression in dementia in secondary analyses. (Am J Geriatr Psychiatry 2019;
&&:&&−&&)INTRODUCTION
D epression is common in dementia with preva-lence of depressive symptoms in people with
dementia ranging between 10% and 62%.1 Depression
in dementia is associated with reduced quality of life,2
exacerbation of cognitive and functional impairment,3
and increased stress and depression in caregivers.4
Effective treatment of depression in dementia is there-
fore a clinical priority. Older clinical guidelines advo-
cate the use of antidepressants for depression in
dementia such as the American Psychiatric Associa-
tion workgroup on Alzheimer’s Disease and other
dementias,5 and as many as 22%−47% of commu-
nity-dwelling persons with dementia are prescribed
antidepressants.6,7 However, the current evidence
from well-designed placebo-controlled trials, as sum-
marized in the most recent 2018 Cochrane review,8
suggests that some early and small trials found posi-
tive results, whereas larger, more recent studies have
been largely negative and that, on balance, there is
little evidence of the efﬁcacy of antidepressants for
depression in dementia. They found that of the eight
studies reviewed, which included 614 participants in
total, the only study that showed signiﬁcant beneﬁt
of antidepressant over placebo on average depressive
symptom severity was the small Depression in
Alzheimer’s Disease Study (DIADS)9. This study
showed a signiﬁcant beneﬁt of sertraline over placebo
on average depressive symptom severity at 12 weeks
in 44 participants. However, the other seven studies,
including the follow-up DIADS-2,10,11 showed no
beneﬁcial effects of antidepressants over placebo,
resulting in a pooled effect size of −0.13 (95% conﬁ-
dence interval [CI]: −0.33 to 0.07) for selective seroto-
nin reuptake inhibitors (SSRIs) and −0.10 (95% CI:
−0.26 to 0.06) for antidepressants in general. There is
however evidence that antidepressants are associatedwith more adverse events than placebo.8,12,13 It is also
the case that relatively few antidepressants have been
trialed in depression in dementia and that further
investigation is needed, particularly of newer medica-
tions.8 As a response to this emerging evidence, the
most recent guidelines suggest that antidepressants
should not be routinely offered as a ﬁrst-line treat-
ment to those with mild to moderate depression in
dementia.14
The Health Technology Assessment Study of the
Use of Antidepressants for Depression in Dementia
(HTA-SADD) trial was a large randomized controlled
trial of the efﬁcacy of sertraline (n = 107) and mirtaza-
pine (n = 108) versus placebo (n = 111) in people with
probable or possible Alzheimer’s disease and depres-
sion.15 In all three groups, an improvement in total
Cornell Scale for Depression in Dementia (CSDD)16
scores was seen from week 0 to week 13, which per-
sisted to week 39. However, sertraline and mirtazapine
did not outperform placebo. This lack of observed anti-
depressant efﬁcacy may in part be owing to the hetero-
geneity of depression in dementia.12 Therefore, there
may be value in evaluating antidepressant efﬁcacy in
subgroups of depression in dementia.
Different symptoms of depression in dementia
may have a different underlying etiology. Some
depressive symptoms, for example, may occur as a
reaction to perceived cognitive deﬁcits, whereas
others may have a common underlying (neuro)
pathology with cognitive deﬁcits.17 For instance, vas-
cular disease and a disruption of frontal-subcortical
pathways may underlie both motivational-related
symptoms of depression (i.e., loss of interest in activi-
ties, psychomotor retardation) and executive deﬁ-
cits.18 Also, the substantial overlap of symptoms of
depression and dementia (e.g., psychomotor change,
apathy, lack of interest, sleep difﬁculties, concentra-
tion problems)19−21 make it possible that symptomsAm J Geriatr Psychiatry&&:&&,&& 2019
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sion. Because different symptoms of depression in
dementia may have a different underlying etiology,
response to antidepressant treatment might differ
according to the depressive symptom proﬁle of the
patient. It would therefore be of clinical relevance if it
were possible to identify subgroups of patients who
might be more likely to respond to antidepressants
based on their symptom proﬁle.Aims of the Study
We therefore completed exploratory secondary
analyses of the HTA-SADD trial data using latent class
analyses (LCA) on the 19 baseline CSDD items to iden-
tify different patient groups and examined the
response to randomized treatment in these subgroups.
We hypothesized that patients with a symptom proﬁle
dominated by core depression items (such as sadness,
pessimism) would respond better to antidepressants
than patients with other symptom proﬁles more likely
to be owing to underlying physical pathology (such as
somatic symptoms and apathy).METHODS
Study Design and Participants
The HTA-SADD was a randomized double-blind
placebo-controlled trial to evaluate the clinical effec-
tiveness of sertraline and mirtazapine in those with
depression in dementia. Details of this study have
been reported previously.15 Participants were
recruited from old-age psychiatry services in nine cen-
ters in England. Inclusion criteria were: 1) National
Institute of Neurological and Communicative Disor-
ders and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria for probable or possible
Alzheimer disease;22 2) co-existing depression of at
least 4 weeks duration assessed as potentially needing
antidepressants as ascertained by the referring psychi-
atrist (however, diagnostic criteria for major depres-
sive disorder were not evaluated); and 3) a CSDD
score of 8 or more ascertained by a trained research
worker. Exclusion criteria were: 1) clinically too criti-
cal for randomization (e.g., suicide risk); 2) absolute
contraindication to trial drugs; 3) already using anti-
depressants; 4) in another trial; and 5) no family orAm J Geriatr Psychiatry&&:&&,&& 2019professional caregiver informant. The study was
approved by the North West 7 (Greater Manchester,
United Kingdom) ethics committee, and consent or
assent was obtained from all participants. The study
is registered under ISRCTN88882979 and EudraCT
2006-000105-38.Randomization and Masking
Participants were independently allocated to receive
placebo, sertraline, or mirtazapine in a ratio of 1:1:1.
Randomization was stratiﬁed by center (n = 9) using a
computer-generated randomization sequence with ran-
domly varying block sizes of three or six. The trial was
double-blind: patients, referring clinicians, research
workers who did baseline and follow-up assessments,
and statisticians were masked to group identity. The
researcher performing the secondary analyses in this
article was not masked for group identity.Dosages of Mirtazapine and Sertraline
Patients in the sertraline and mirtazapine group
started on 50 mg for sertraline and 15 mg for mirtaza-
pine. Over the ﬁrst 2 weeks, the dosage was increased
to 100 mg for sertraline and 30 mg for mirtazapine. At
4 weeks, the CSDD was re-administered: if the CSDD
score was 4 or higher the dosage was increased to the
maximum of 150 mg for sertraline and 45 mg of mirta-
zapine. If the CSDD score was below 4 the CSDD was
administered again at 8 weeks, and the dosage was
increased to 150 mg for sertraline and 45 mg for mirta-
zapine if the score was 4 or higher. After 8 weeks, clini-
cians were free to adjust the dose.Assessment of Depressive Symptoms
At baseline, at 13 weeks, and at 39 weeks after base-
line, the CSDD16 was administered by a trained
research worker who interviewed both the patient and
the caregiver. The CSDD includes 19 questions that
can be rated 0 (absent), 1 (mild), or 2 (severe). There-
fore, the total score ranges from 0−38, with higher
scores denoting higher severity of depression.Baseline Characteristics
The following caregiver-rated scores were com-
pleted at baseline, prior to randomization: participant3
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physical subscales, European Quality of Life Scale-
Visual Analog Scale, and DEMQOL-Proxy), participant
activity limitation (Bristol Activities of Daily Living),
participant neuropsychiatric symptoms (Neuropsychi-
atric Inventory [NPI]), caregiver mental health (12-item
General Health Questionnaire), and caregiver burden
(Zarit Burden Interview score). The following partici-
pant-rated scores were assessed at baseline: participant
cognition (Mini Mental State Examination), and partici-
pant quality of life (European Quality of Life Scale-
Visual Analog Scale and DEMQOL). To assess demen-
tia vascularity, a modiﬁed Hachinski ischemic score
was calculated at baseline.Analyses
All participants that were included at baseline
(n = 326) were assigned into different classes accord-
ing to their endorsed symptom proﬁle by performing
LCA23,24 on the 19 items of the baseline CSDD. Before
entering into the LCA, responses to the CSDD items
were dichotomized into absent or present. Models
with one to six classes were ﬁtted using maximum
likelihood estimator with robust standard errors. The
optimal number of classes was determined by com-
paring ﬁt statistics, interpretability of the classes, and
absence of overly small classes (n <30). Details of the
LCA can be found in the supplementary material.
After the LCA, we described baseline characteristics
for each class separately using one-way analysis of vari-
ance for normally distributed continuous variables, the
Kruskal-Wallis test for not normally distributed contin-
uous variables, and the x2 test for categorical variables.
After this, we evaluated whether the LCA groups dif-
fered in response to sertraline or mirtazapine over time
by calculating a three-way interaction between LCA-
class£ randomization arm£ time. For this purpose,
we used linear mixed models using a marginal model
with unstructured covariance between the different
time-points, and CSDD score at baseline, week 13 and
39 as dependent variable. Independent variables (and
ﬁxed effects) in this model were LCA class, randomiza-
tion arm, time, the three-way interaction LCA-
class£ randomization arm£ time, and clinical center
where participants were recruited. In case of a statisti-
cally signiﬁcant three-way interaction, we calculated
the two-way interaction between randomization
arm£ time in each of the classes separately using linear4mixed models (again, a marginal model with unstruc-
tured covariance between the different time-points, and
total CSDD score as dependent variable). Independent
variables (and ﬁxed effects) in these models were: time
(categorical variable indicating 0, 13, or 39 weeks), ran-
domization arm, the interaction between time£ ran-
domization arm, and clinical center where participants
were recruited. In case of a signiﬁcant effect of
time£ randomization arm, estimated differences from
placebo were reported for sertraline and mirtazapine at
13 and 39 weeks, and Hedges g was calculated to esti-
mate the effect size. LCA was performed in Mplus ver-
sion 7 (Muthen & Muthen),25 and the other statistics in
IBM SPSS Statistics version 22 (IBM Corporation,
Armonk, NY).
RESULTS
Participants
A total of 326 participants were randomly assigned
to placebo (n = 111), sertraline (n = 107), and mirtaza-
pine (n = 108). At 13 weeks, 258 completed the CSDD
(placebo: n = 95; sertraline: n = 78; mirtazapine: n = 85),
and at 39 weeks, 226 completed the CSDD (placebo:
n = 82; sertraline: n = 68; mirtazapine: n = 76).Results of the LCA
The optimal solution of the LCA yielded four clas-
ses: 1) a “severe” class; 2) a “psychological” class with
relatively severe endorsement of psychological symp-
toms (pessimism and low self-esteem) and absence of
sleep problems; 3) an “affective” class with relatively
low endorsement of psychological items and absence
of appetite problems; and 4) a “somatic” class with
mainly somatic symptoms and less affective/mood
symptoms (Supplementary Figure 1). Details of the
LCA results and the selection of the optimal number of
classes can be found in the Supplementary material.Baseline Characteristics for Each of the Four
Classes
Patients in class 1 (severe symptoms) had worse
quality of life scores, worse total CSDD scores, and
higher NPI scores on depression and anxiety compared
with patients in all other classes. They also had higherAm J Geriatr Psychiatry&&:&&,&& 2019
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with patients in classes 2 and 3 (psychological and
affective symptoms, respectively), and worse Bristol
Activities of Daily Living scores compared with
patients in class 2 (psychological symptoms). Patients
in class 4 (somatic symptoms) had worse total CSDD
scores than patients in class 2 (psychological symp-
toms) (Table 1).Impact of Randomization Arm on Course Over
Time of Total CSDD Scores in Each Class
Results of the linear mixed model analysis showed a
statistically signiﬁcant three-way interaction between
LCA-class£ randomization arm£ time (F (28, 368.1)
= 2.474; p <0.001). The two-way interaction randomi-
zation arm£ time was statistically signiﬁcant only in
class 2 (psychological symptoms; Table 2). Speciﬁcally,
mirtazapine outperformed placebo at 13 weeks for
patients in this subgroup with psychological symp-
toms (class 2). Based on the linear mixed model, the
adjusted difference in change score baseline to 13
weeks was −2.77 points; 95% CI: −5.09 to −0.46;
t (df) =−2.39 (68.2); p = 0.019 (Table 2). This effect per-
sisted to 39 weeks but lost statistical signiﬁcance
(adjusted difference based on the linear mixed model
baseline to 39 weeks: −2.97; 95% CI: −6.15 to 0.20;
t (df) =−1.87 (58.2); p = 0.066; Table 2). Mirtazapine
did not outperform placebo at week 13 and 39 in the
remaining three groups. The Hedges g (standard error)
for mirtazapine versus placebo was 0.70 (0.31) at week
13 and 0.65 (0.34) at week 39. Sertraline did not outper-
form placebo at week 13 and week 39 in all four
groups (Table 2). Figure 1 shows the time-course
of absolute unadjusted mean (95% CI) CSDD scores
at baseline, 13 weeks and 39 weeks for each class
separately.
DISCUSSION
Main Findings
To the best of our knowledge, this is the ﬁrst study
to explore antidepressant efﬁcacy in subgroups of
depression in dementia with different depressive symp-
tom proﬁles. In these exploratory secondary analyses,
we identiﬁed that a “psychological” subgroup with
affective symptoms, relatively severe endorsement ofAm J Geriatr Psychiatry&&:&&,&& 2019psychological symptoms (pessimism and low self-
esteem), and an absence of sleep problems appeared to
respond better to mirtazapine compared with placebo.
Those in this “psychological” subgroup receiving mir-
tazapine improved on average almost three CSDD
points (95% CI: −5.1 to −0.5 points) more than those
receiving placebo from week 0 to week 13, which was
sustained to week 39. At week 39, the difference with
baseline was as high as at week 13, but lost statistical
signiﬁcance due to smaller group sizes. The beneﬁcial
effects of mirtazapine compared with placebo in this
group correspond to effect sizes (standard error) of 0.70
(0.31) at week 13 and 0.65 (0.34) at week 39, which
would be considered moderate or medium effect sizes.
Antidepressant treatment was not effective in reducing
depression in any of the other subgroups. It is impor-
tant to note that this is an exploratory secondary analy-
sis from a study in which the primary ﬁndings were
negative. As such, these data are in no way deﬁnitive
and would beneﬁt from replication.Comparison to Literature
In the DIADS of 44 people with depression in
Alzheimer disease, response to sertraline was
observed to be highest on the mood subscale of the
CSDD compared with other instruments.26 In the
larger DIADS-2, there was no differential response
to sertraline compared with placebo in subgroups
of depression in dementia with 1) major depression;
2) minor depression; and 3) Alzheimer-associated
affective disorder.27
Studies have evaluated antidepressant efﬁcacy on
speciﬁc depressive symptoms and symptom proﬁles
in depressed populations without dementia. Patients
with depression without dementia were not the sub-
ject of this study, and there will be major limitations
in generalizability from populations without demen-
tia to those with dementia. However, these studies do
provide an illustration of the potential for exploration
of differential response in subgroups of people with
depression. A pooled analysis from 32 randomized
controlled trials evaluating the efﬁcacy of an SSRI
against placebo found that SSRIs were more effective
in improving mood than in reducing other symptoms
of depression.28 Secondary analyses from the
Sequenced Treatment Alternatives to Relieve Depres-
sion and the Combining Medications to Enhance
Depression Outcomes trials showed that core5
TABLE 1. Association of Baseline Characteristics With Class
Class 1:
Severe
(n = 34)
Class 2:
Psychological
(n = 86)
Class 3:
Affective
(n = 129)
Class 4:
Somatic
(n = 77)
Overall
statistic (df);
p value
Significant group
differenced
Age (years), mean (SD) 78.0 (10.4) 79.1 (7.9) 79.5 (8.6) 80.1 98.1) F (3, 322) = 0.5; p = 0.672
Sex (male), n (%) 12 (35.3) 32 (37.2) 46 (35.7) 15 (19.5) x2 (3) = 7.6; p = 0.056
Ethnicity (white), n (%) 31 (91.2) 83 (96.5) 121 (93.8) 68 (88.3) x2 (3) = 4.5; p = 0.213
Marital status (married): n = 311, n (%) 13 (40.6) 50 (60.2) 61 (47.7) 35 (51.5) x2 (3) = 4.8; p = 0.188
Lives in care home, n (%) 5 (14.7) 10 (11.6) 24 (18.6) 11 (14.3) x2 (3) = 2.0; p = 0.563
Duration of depression: n = 319
<1 month, n (%) 2 (5.9) 2 (2.3) 5 (4.1) 1 (1.3) x2 (9) = 12.0; p =
1−2 months, n (%) 0 (0.0) 4 (4.7) 8 (6.6) 8 (10.4) 0.214
2−6 months, n (%) 7 (20.6) 12 (14.0) 30 (24.6) 19 (24.7)
>6 months, n (%) 25 (73.5) 68 (79.10 79 (64.8) 49 (63.6)
Dementia vascularity: modified HIS score;
n = 240; mean (SD)
2.4 (1.2) 2.0 (1.3) 2.2 (1.3) 2.1 (1.4) F (3, 236) = 0.7; p = 0.574
Total CSDD scorea at baseline: n = 322;
mean (SD)
20.5 (5.3) 11.4 (3.0) 12.2 (3.1) 13.0 (3.2) F (3, 318) = 64.1; p <0.001 1 versus 2: t (df) = 9.3 (40.0);
p <0.001
1 versus 3: t (df) = 8.7 (37.6);
p <0.001
1 versus 4: t (df) = 7.6 (42.7);
p <0.001
2 versus 4: t (df) =−3.12 (158.0);
p = 0.002
Randomization arm
Placebo (n = 111), n (%) 14 (41.2) 28 (32.6) 45 (34.9) 24 (31.2) x2 (6) = 2.1; p =
Sertraline (n = 107), n (%) 8 (23.5) 29 (33.7) 42 (32.6) 28 (36.4) 0.913
Mirtazapine (n = 108), n (%) 12 (35.3) 29 (33.7) 42 (32.6) 25 (32.5)
Participant rated scores
Cognition (MMSEb): n = 251,
mean (SD)
18.5 (6.6) 18.4 (6.4) 17.5 (7.2) 18.5 (6.4) F (3, 247) = 0.4; p = 0.719
Participant generic quality of life: Euro-
QOLb-VAS (0−100): n = 269,
mean (SD)
51.3 (21.3) 64.9 (21.3) 66.1 (19.9) 67.4 (18.5) F (3, 265) = 4.7; p = 0.003 1 versus 2: t (df) =−2.90 (102.0);
p = 0.005
1 versus 3: t (df) =−3.47 (134.0);
p = 0.001
1 versus 4: t (df) =−3.59 (83.0);
p = 0.001
Participant disease-specific quality of life:
DEMQOLa (28−112): n = 260, mean (SD)
69.9 (18.7) 82.9 (13.4) 85.1 (14.6) 89.1 (10.8) F (3, 256) = 11.7; p <0.001 1 versus 2: t (df) =−3.24 (34.5);
p = 0.003
1 versus 3: t (df) =−4.46 (127.0);
p <0.001
1 versus 4: t (df) =−4.87 (32.7);
p <0.001
2 versus 4: t (df) =−2.94 (129.0);
p = 0.004
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TABLE 1. (continued)
Class 1:
Severe
(n = 34)
Class 2:
Psychological
(n = 86)
Class 3:
Affective
(n = 129)
Class 4:
Somatic
(n = 77)
Ove
statisti
p va
Significant group
differenced
Carer rated scores
BADLa (n = 324), mean (SD) 21.4 (11.4) 15.2 (11.6) 18.1 (10.1) 18.4 (11.4) F (3, 320) = 2 0.035 1 versus 2: t (df) = 2.64 (118.0);
p = 0.009
Participant SF-12b physical component:
n = 300, mean (SD)
48.1 (14.1) 46.7 (13.5) 49.3 (10.7) 47.7 (10.8) F (3, 296) = 0 0.508
Participant SF-12b mental component:
n = 300, mean (SD)
44.0 (11.6) 45.3 (11.8) 45.2 (11.3) 46.7 (11.1) F (3, 296) = 0 0.691
Participant generic quality of life:
EuroQOL-VASb (0−100): n = 320,
mean (SD)
39.7 (22.0) 52.2 (19.2) 56.4 (19.7) 52.4 (22.9) F (3, 316) = 5 0.001 1 versus 2: t (df) =−3.06 (116.0);
p = 0.003
1 versus 3: t (df) =−4.24 (157.0);
p <0.001
1 versus 4: t (df) =−2.71 (107.0);
p = 0.003
Participant disease-specific quality of
life DEMQOL-Proxya (31−124): n = 279,
mean (SD)
77.6 (14.9) 85.7 (13.0) 89.0 (14.9) 89.9 (14.4) F (3, 275) = 5 0.001 1 versus 2: t (df) =−2.69 (99.0);
p = 0.009
1 versus 3: t (df) =−3.58 (134.0);
p<0.001
1 versus 4: t (df) =−3.76 (94.0);
p <0.001
Carer mental health: GHQ-12 (0−36)a:
n = 306, mean (SD)
13.5 (4.5) 12.5 (5.2) 12.5 (5.2) 12.9 (5.8) F (3, 302) = 0 0.757
Carer burden: ZBI score (0−88)a: n = 271,
mean (SD)
31.6 (14.9) 28.2 (15.5) 26.9 (16.2) 24.6 (15.2) F (3, 267) = 1 0.279
Participant neuropsychiatric symptoms (NPI)a, IQR
Delusions (n = 108) 3; 6; 8 2; 3; 6 2; 3; 5 1; 4; 7 H (3) = 6.21; 02
Hallucinations (n = 71) 2; 4; 5 3; 5; 5 3; 4; 5 2; 4; 5 H (3) = 3.75; 89
Agitation (n = 215) 2; 4; 6 1; 3; 4 2; 3; 6 2; 3; 6 H (3) = 4.80; 87
Depression (n = 313) 4; 7; 8 2; 4; 8 2; 3; 6 2; 3; 6 H (3) = 18.27 01 1 versus 2: U = 836.0; p <0.001;
1 versus 3: U = 1180.5; p <0.001;
1 versus 4: U = 645.5; p <0.001
Anxiety (n = 235) 3; 6; 8 2; 3; 6 2; 4; 6 2; 3; 6 H (3) = 7.90; 48 1 versus 2: U = 708.5; p = 0.018;
1 versus 3: U = 982.5; p = 0.024;
1 versus 4: p = 0.009
Elation (n = 30) 1; 2; NAc 1; 2; 2 2; 3; 3 1; 2; 4 H (3) = 3.29; 49
Disinhibition (n = 104) 2; 2; 3 1; 2; 3 1; 3; 4 1; 2; 6 H (3) = 0.24; 71
Irritability (n = 228) 2; 4; 6 2; 3; 6 2; 3; 6 1; 4; 8 H (3) = 2.35; 02
Apathy (n = 254) 4; 8; 8 3; 4; 8 2; 4; 8 3; 4; 8 H (3) = 6.98; 73
Aberrant motor behavior (n = 171) 3; 4; 8 2; 4; 6 3; 6; 8 3; 4; 8 H (3) = 3.78; 86
Sleep and night-time behavior disorders
(n = 155)
3; 4; 7 3; 4; 4 3; 4; 8 3; 4; 8 H (3) = 1.53; 76
(continued on next page)
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Sertraline and Mirtazapine Versus Placebo in Subgroups
8emotional symptoms (low mood, loss of interest, feel-
ings of worthlessness) responded better to antidepres-
sants than sleep symptoms, and sleep symptoms
responded better to antidepressants than atypical
symptoms (suicidality, psychomotor agitation/retar-
dation, and hypersomnia).29 The efﬁcacy of antide-
pressant treatment on these different symptom
clusters differed according to drug. For instance, core
emotional symptoms responded better to high-dose
duloxetine and paroxetine than escitalopram, which
performed equal to placebo in reducing core emo-
tional symptoms.29 In the Genome-Based Therapeutic
Drugs for Depression study, mood and cognitive
symptoms improved more with escitalopram than
with nortriptyline, whereas neurovegetative symp-
toms improved more with nortriptyline than escitalo-
pram.30 In a randomized controlled trial of 231
patients with depression, paroxetine treatment and
cognitive therapy were associated with a greater
reduction in cognitive/suicide symptoms relative to
placebo, and cognitive therapy was associated with a
greater reduction in atypical-vegetative symptoms
than placebo or paroxetine.31
Although these speciﬁc ﬁndings cannot be general-
ized directly to depression in dementia, taken with
the data presented here, it is possible that antidepres-
sant treatments may be more beneﬁcial for patients
with relatively high endorsement of core mood and
psychological symptoms than for patients with more
of other (e.g., vegetative or atypical) symptoms of
depression.Interpretation and Clinical Implications
The results of the present analyses should be
interpreted with caution, because they are based on
exploratory secondary analyses in small groups.
Small group size, or lack of power, not only results
in false-negative ﬁndings, but also may result in
false-positive ﬁndings.32 Before making any conclu-
sions, it is therefore essential that these results are
replicated. Furthermore, it is counterintuitive that
mirtazapine (a sedating drug that is often pre-
scribed in patients with sleep problems) was effec-
tive in a subgroup without sleep problems, whereas
sertraline is not effective in reducing depression in
any of the four subgroups. This counterintuitive
ﬁnding requires further investigation.Am J Geriatr Psychiatry&&:&&,&& 2019
TABLE 2. Impact of Randomization Arm on Course Over Time of Total CSDD Scores in Each Class Separatelya
Class 1: Severe Symptoms
Placebo Sertraline Mirtazapine
n CSDD score n CSDD score n CSDD score
Baseline, mean (SD) 13 22.8 (7.2) 8 19.3 (2.1) 12 19.0 (3.6)
Week 13, mean (SD) 11 11.4 (6.1) 6 9.5 (7.4) 10 10.5 (5.4)
Week 39, mean (SD) 11 11.7 (7.4) 6 13.0 (7.2) 9 14.3 (10.0)
Treatment£ time interactiona F (4, 24.2) = 0.540; p = 0.708
Class 2: Psychological Symptoms
Placebo Sertraline Mirtazapine
n CSDD score n CSDD score n CSDD score
Baseline, mean (SD) 28 11.5 (3.2) 29 11.6 (3.0) 28 11.3 (2.8)
Week 13, mean (SD) 22 8.2 (4.2) 25 8.5 (4.9) 22 5.3 (3.1)
Week 39, mean (SD) 17 7.3 (3.4) 19 9.2 (5.4) 19 4.8 (4.0)
Treatment£ time interactiona F (4, 61.2) = 2.827; p = 0.032
Mean difference from placebo based on the linear mixed model (SE, 95% CI; t (df); p value)a
13 weeks 47 0.31 (1.13; −1.93 to 2.56; t
(df) = 0.28 (68.0); p = 0.783)
44 −2.77 (1.16; −5.09 to −0.46; t
(df) =−2.39 (68.2); p = 0.019)
39 weeks 36 1.41 (1.57; −1.73 to 4.56; t
(df) = 0.90 (59.2); p = 0.372)
36 −2.97 (1.59; −6.15 to 0.20; t
(df) =−1.87 (58.2); p = 0.066)
Class 3: Affective Symptoms
Placebo Sertraline Mirtazapine
n CSDD score n CSDD score n CSDD score
Baseline, mean (SD) 45 12.4 (3.4) 42 12.0 (2.8) 42 12.1 (2.9)
Week 13, mean (SD) 40 7.0 (3.1) 28 8.7 (4.6) 33 8.5 (5.3)
Week 39, mean (SD) 33 7.2 (5.0) 25 8.2 (5.1) 29 8.5 (5.8)
Treatment£ time interactiona F (4, 98.0) = 1.023; p = 0.400
Class 4: Somatic Symptoms
Placebo Sertraline Mirtazapine
n CSDD score n CSDD score n CSDD score
Baseline, mean (SD) 24 13.7 (3.2) 27 13.4 (3.7) 24 11.8 (2.3)
Week 13, mean (SD) 20 6.9 (3.8) 19 8.4 (4.8) 21 7.0 (5.2)
Week 39, mean (SD) 20 10.1 (5.9) 16 7.2 (4.8) 18 6.3 (3.9)
Treatment£ time interactiona F (4, 57.8) = 1.689; p = 0.165
a Estimates of the mean (SD) were based on the final adjusted linear mixed model. Independent variables (and fixed effects) in these models
were: time (0, 13, or 39 weeks), randomization arm, the interaction between time£ randomization arm, and clinical center where participants
were recruited. In case of a statistically significant time£ randomization interaction, the lower part of the table shows the mean difference with
placebo (with SE; 95% CI, t value, df, and p value). SD: standard deviation; SE: standard error.
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Zuidersma et al.Another methodological issue is that patients in all
three arms, including the placebo-group, improved con-
siderably. This improvement may be due to artifacts
such as regression to the mean, the Hawthorne effect,
or the natural course of depression in dementia.
This last possibility is less likely because 221 of 326
participants had been depressed for more than
6 months before randomization. Perhaps the greatest
contributor to the improvements in depression is the
non-drug treatment as usual by the old-age psychiatry
services. This treatment as usual is personalized, includ-
ing a broad range of supportive and problem-solvingAm J Geriatr Psychiatry&&:&&,&& 2019interventions, and is commonly delivered by a commu-
nity psychiatric nurse in the patient’s own household.
Antidepressants may not be effective over and above
the effects of this personalized non-drug intervention.
In the context of conﬂicting conclusions in clinical
guidelines,5,14 clinicians should continue to be cau-
tious in prescribing antidepressants in people with
dementia. Surprisingly, in the “severe” depression
subgroup, no beneﬁcial effects of sertraline and mirta-
zapine were found at 13 weeks, with worse (but sta-
tistically non-signiﬁcant) effects at 39 weeks. This is
important as general guidelines for treatment of9
FIGURE 1. Unadjusted mean CSDD scores by treatment group for each class separately. Class 1: severe; class 2: psychological; class
3: affective; class 4: somatic. Lowest score is best. Error bars show 95% CI. *Difference with placebo: p <0.05.
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Sertraline and Mirtazapine Versus Placebo in Subgroupsclinical depression,33,34 as well as the updated clinical
guideline National Institute for Health and Care
Excellence 2018 for depression in dementia,14 have
different guidelines according to initial depression
severity, and thus, physicians generally rely on the
severity of the depression rather than symptom pro-
ﬁle when starting drug treatment. However, a recent
individual patient data meta-analysis also concluded
that antidepressant efﬁcacy does not differ according
to initial depression severity.3510Strengths and Limitations
This study uses the data from the largest com-
pleted double-blind randomized placebo-controlled
trial of depression in dementia. Because of the large
sample size, we were able to explore antidepressant
efﬁcacy in subgroups of depression in dementia.
However, these results must also be interpreted
with caution. The ﬁrst and most important limita-
tion of the analyses reported here is that this is aAm J Geriatr Psychiatry&&:&&,&& 2019
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Zuidersma et al.set of secondary analyses and the sample size for
these subgroup analyses is smaller than for the pri-
mary outcomes. The relatively small sizes of the
subgroups and the number of analyses may have
resulted in both lack of power, and positive ﬁnd-
ings due to chance. Therefore, the results reported
should be interpreted cautiously and before making
any conclusions, replication of these ﬁndings is
needed. Second, although data driven, the interpre-
tation of the LCA and the choice of the optimal
number of classes has an element of subjectivity.
The four-class model was chosen based on the Boot-
strap Likelihood Ratio Test and the interpretability
of the classes of the four-class model and the small
sample sizes of the ﬁve- and six-class models. How-
ever, the BIC preferred the two-class model. Third,
the study included only sertraline and mirtazapine,
whereas studies in depressed non-demented popu-
lations have found evidence that efﬁcacy on speciﬁc
symptoms might vary for different antidepressants.
Fourth, data on non-drug interventions outside the
study protocol were not gathered. There is a possi-
bility that the observed differences might have been
inﬂuenced by non-drug treatments for depression
outside the study protocol; however, the randomi-
zation should have assorted these equally across
the three intervention groups.
CONCLUSIONS
Because of the exploratory nature of the analyses
and the small sample sizes for subgroup analysis,
there is the need for caution in interpreting these
data. Replication of the potential effects of mirtaza-
pine in the subgroup of those with depression in
dementia with “psychological” symptoms would be
valuable. These data should not change current clini-
cal practice. Nevertheless, these analyses demon-
strate the potential value of stratifying groups of
depression in dementia and examining differential
effectiveness in subgroups of depression in dementia
when studying the efﬁcacy of depression treatment.
Future studies should consider complementing clini-
cally derived symptom proﬁles with empiricallyAm J Geriatr Psychiatry&&:&&,&& 2019derived phenotypes when evaluating the efﬁcacy of
other antidepressant or psychological treatments
across subgroups.
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